Insights
Insights From Our Experts
Articles
Gross-To-Net: Challenges and Best Practices
Clinical pathways are necessary in guarding against perverse financial incentives that encourage drug overutilization and underutilization. Moving forward, the more diligent payers and integrated delivery networks can be in evaluating and incorporating utilization criteria when establishing…
Breaking Up Is Hard to Do: When to Leave Your CRO for Optimized Pharmacovigilance
During an intense year for biopharma innovation, the industry’s rapid growth is spotlighting a global need to bring pharmacovigilance practices up to speed. Executing superior pharmacovigilance practices from clinical trials throughout the product life cycle is…
Pharma’s Push and Pull: Products Approved Amid Government Pushes for Regulation and Pricing Change: April 2021
Global healthcare and life sciences innovation continues to surge at an unprecedented rate, and government entities worldwide are trying to keep up. Price transparency and treatment affordability remain at the top of the list for legislative concern. For instance, United States…
The Secret’s Out: The Impact of Net Price Transparency
Pricing system pressures are increasing for the top four markets in Europe. Price transparency, changes to public health plans and curative therapies are set to disrupt traditional drug pricing. To navigate this ever-shifting landscape, companies must…
Audit From Anywhere: Upgrade Your Quality System Audit Programs
As the world strives every day to adapt to changes this year, one change that pharma manufacturers are adapting to is the impact of COVID-19 on product safety audits. From supplier audits to evaluating internal or affiliated sites with…
Learning How to Play Dilution Dodgeball
The healthcare industry is reaching new heights in innovation, and as new drugs are founded, owners of biotech companies must decide whether or not they want to independently bring their product to market. Developing and successfully commercializing a…
WODC Online 2021: Commercializing Advanced Therapies for Rare Diseases
Innovative rare disease therapies deserve innovative commercialization strategies. With over 1,200 attendees from across the globe, the World Orphan Drug Congress featured one full day of virtual panels and presentations dedicated to drug development and commercialization.…
Visualizing EVERSANA’s Omnichannel Activation Model
The pharma industry’s needs have evolved beyond one-dimensional playbooks, disconnected promotional efforts and limited ability to assess stakeholder engagement. Manufacturers need to adopt an omnichannel model that goes beyond “marketing” to provide actionable insights that better…
Pharmaceutical Opportunities and Challenges Facing Long-Term Care Facilities
Skilled nursing facilities (SNF) and long-term care (LTC) facilities have been a major source for news stories throughout the COVID-19 pandemic due to the devastation brought to patient populations. Now, pharmaceutical manufacturers have an opportunity to…
Ask the Expert: How to Maximize Your Omnichannel Strategy
Omnichannel strategies are transforming the way consumers interact with brands across industries – from the all-in-one Magic Band experience at Disney to buying your favorite latte with the Starbucks app. The pharmaceutical industry is no exception,…